1. Тактика выявления частых и редких типов химерного транскрипта BCR-ABL при хроническом миелоидном лейкозе / О. В. Никулина [и др.] // Клин. онкогематология. Фундам. исслед. и клин. практика. – 2015. – Т. 8, № 2. – С. 161–168.

2. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors / L. Falchi [et al.] // Am. J. Hematol. – 2013. – Vol. 88, N 12. – P. 1024–1029. https://doi. org/10.1002/ajh.23560

3. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against cancer program / J. Gabert [et al.] // Leukemia. – 2003. – Vol. 17, N 12. – P. 2318–2357. https://doi.org/10.1038/sj.leu.2403135

4. European Leukemia Net recommendations for the management of chronic myeloid leukemia / M. Baccarani [et al.] // Blood. – 2013. – Vol. 122, N 6. – P. 872–884. https://doi.org/10.1182/blood-2013-05-501569

5. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in Imatinib-treated chronic myeloid leukemia patients / I. Iacobucci [et al.] // Clin. Cancer Res. – 2006. – Vol. 12, N 10. – P. 3037–3042. https://doi.org/10.1158/1078-0432.ccr-05-2574

6. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with Imatinib Mesylate / J. Cortes [et al.] // Clin. Cancer Res. – 2005. – Vol. 11, N 9. – P. 3425–3432. https://doi.org/10.1158/1078-0432.ccr-04-2139

7. Куцев, С. И. Значение анализа мутаций гена BCR-ABL в оптимизации таргетной терапии хронического миелолейкоза / С. И. Куцев, М. В. Вельченко // Клин. онкогематология. Фундам. исслед. и клин. практика. – 2008. – Т. 1, № 3. – С. 190–199.

8. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project / J. W. W. Coebergh [et al.] // Eur. J. Cancer. – 2006. – Vol. 42, N 13. – P. 2019–2036. https://doi.org/10.1016/j.ejca.2006.06.005

9. Suttorp, M. Chronic myeloid leukemia in children: diagnostics and management / M. Suttorp, J. Tabea Tauer, F. Millot // Third midsummer meeting on pediatric hematology and oncology, 10–12 June, Liberec / Department of Paediatric Haematology and Oncology [et al.]. – Prague, 2011. – P. 12–13.

10. Three decades of transplantation for chronic myeloid leukemia: what have we learned? / J. Pavlu [et al.] // Blood. – 2011. – Vol. 117, N 3. – P. 755–763. https://doi.org/10.1182/blood-2010-08-301341

11. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial / F.-X. Mahon [et al.] // Lancet Oncol. – 2010. – Vol. 11, N 11. – P. 1029–1035. https://doi.org/10.1016/s1470-2045(10)70233-3

12. Suttorp, M. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation / M. Suttorp, F. Millot // Hematology. – 2010. – Vol. 2010, N 1. – P. 368–376. https://doi.org/10.1182/ asheducation-2010.1.368

13. Wei, G. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib / G. Wei, S. Rafiyath, D. Liu // J. Hematol. Oncol. – 2010. – Vol. 3, N 1. – Art. 47. https://doi.org/10.1186/1756-8722-3-47

14. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-Paed I / M. Suttorp [et al.] // Klinische Pädiatrie. – 2009. – Vol. 221, N 6. – P. 351–357. https://doi.org/10.1055/ s-0029-1239529

15. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias / C. GambacortiPasserini [et al.] // Lancet Oncol. – 2003. – Vol. 4, N 2. – P. 75–85. https://doi.org/10.1016/s1470-2045(03)00979-3

16. Management and clinical outcome of CML patients after imatinib resistance associated with ABL kinase domain mutations / S. Kreill [et al.] // Blood. – 2003. – Vol. 102, N 11. – P. 71A.

17. Shah, N. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemia / N. Shah, C. Sawyers // Oncogene. – 2003. – Vol. 22, N 47. – P. 7389–7395. https://doi.org/10.1038/sj.onc.1206942

18. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib / H.-K. Al-Ali [et al.] // Hematology. – 2004. – Vol. 5, N 1. – P. 55–60. https://doi.org/10.1038/sj.thj.6200319

19. Hochhaus, A. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance / A. Hochhaus, P. La Rosée // Leukemia. – 2004. – Vol. 18, N 8. – P. 1321–1331. https://doi.org/10.1038/sj.leu.2403426

20. Branford, S. Chronic myeloid leukemia: molecular monitoring in clinical practice / S. Branford // Hematology. – 2007. – Vol. 2007, N 1. – P. 376–383. https://doi.org/10.1182/asheducation-2007.1.376

21. Correlation of BCR/ABL transcript variants with patients characteristics in childhood chronic myeloid leukaemia / R. Adler [et al.] // Eur. J. Haematol. – 2009. – Vol. 82, N 2. – P. 112–118. https://doi.org/10.1111/j.1600-0609.2008.01170.x